Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations

The Lancet Haematology - Tập 6 - Trang e366-e374 - 2019
Jacob D Soumerai1,2,3, Ai Ni4, Mohamed Darif5, Anil Londhe5, Guan Xing6, Yong Mun7, Neil E Kay8, Tait D Shanafelt8,9, Kari G Rabe8, John C Byrd10, Asher A Chanan-Khan11, Richard R Furman12, Peter Hillmen13, Jeffrey Jones10, John F Seymour14, Jeffrey P Sharman15, Lucille Ferrante5, Mehrdad Mobasher7, Thomas Stark7, Vijay Reddy16
1Massachusetts General Hospital Cancer Center, Boston, MA, USA
2Harvard Medical School, Boston, MA, USA
3Memorial-Sloan Kettering Cancer Center, New York, NY, USA
4Memorial Sloan-Kettering Cancer Center, New York, NY, USA
5Janssen Pharmaceuticals, Horsham, PA, USA
6Gilead Sciences, Seattle, WA, USA
7Genentech, South San Francisco, CA, USA
8Mayo Clinic, Rochester, MN, USA
9Stanford University Medical Center, Stanford, CA, USA
10Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
11Mayo Clinic, Jacksonville, FL USA
12Weill Cornell Medical College & New York Presbyterian Hospital, New York, NY, USA
13St James's University Hospital, Leeds, UK
14Peter MacCallum Cancer Centre, Royal Melbourne Hospital, The University of Melbourne, Melbourne, VIC, Australia
15Willamette Valley Cancer Institute and Research Center, Eugene, OR, USA
16Pharmacyclics, Sunnyvale, CA, USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

The Lancet Haematology

Tập 6

e366-e374

Thông tin tác giả